Advertisement

Evaluation of Compounds That Prevent Reactivation of HIV-1 in OM-10.1 Cells

  • Salvatore T. Butera
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 24)

Abstract

It is critically important that new therapeutic compounds and targets for therapeutic intervention be identified in the battle against the human immunodeficieny virus type 1(HIV-1). Many of the currently existing therapeutic approaches target virus-specific factors involved in steps along the HIV-1 life cycle prior to proviral integration. These preintegrative or afferent therapeutic approaches initially appeared quite promising (like reverse transcriptase [RT] inhibitors and soluble CD4) but have shown disappointing clinical benefit. With the recent appreciation of suppression of HIV-1 fusion by selected chemokines, more development of afferent inhibitors is certainly on the horizon.

Keywords

Sodium Butyrate Complete Growth Medium Therapeutic Compound Afferent Inhibitor Efferent Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Butera, S. T. and Folks, T. M. (1992) Application of latent HIV-1 infected cellular models to therapeutic intervention. AIDS Res. Human Retroviruses 8, 991–995.CrossRefGoogle Scholar
  2. 2.
    Butera, S. T., Perez, V. L., Wu, B.-Y., Nabel, G. J., and Folks, T. M. (1991) Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J. Virol. 65, 4645–4653.PubMedGoogle Scholar
  3. 3.
    Critchfield, J. W., Butera, S. T., and Folks, T. M. (1996) Inhibition of HIV activation in latently infected cells by flavonoid compounds. AIDS Res. Human Retroviruses 12, 39–46.CrossRefGoogle Scholar
  4. 4.
    Butera, S. T., Roberts, B. D., Critchfield, J. W., Fang, G., McQuade, T., Gracheck, S. J., and Folks, T. M. (1995) Compounds that target novel cellular components involved in HIV-1 transcription. Mol. Med. 1, 758–767.PubMedGoogle Scholar
  5. 5.
    Feorino, P. M., Butera, S. T., Folks, T. M., and Schinazi, R. F. (1993) Prevention of activation of HIV-1 by antiviral agents in OM-10.1 cells. Antiviral Chem. Chemother. 4, 55–63.Google Scholar
  6. 6.
    Besansky, N. J., Butera, S. T., Sinha, S., and Folks, T. M. (1991) Unintegrated human immunodeficiency virus type 1 DNA in chronically infected cell lines is not correlated with surface CD4 expression. J. Virol. 65, 2695–2698.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Salvatore T. Butera

There are no affiliations available

Personalised recommendations